Zymeworks Inc.

We're excited to share that our partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating our HER2-targeted therapy at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. Learn more: loom.ly/Atc1WAI #AACR26

#AACR26 is an incredible opportunity to connect with the life sciences community, exchange insights, and help drive cancer research forward. We’re excited to present clinical and preclinical data from our #ADC programs at at this year’s AACR Annual Meeting, including: - New clinical data from our Phase 1 trial of ZW191 in an oral presentation on April 21 - Preclinical data highlighting combination potential for ZW191 - New ADC candidates, including ZW437 and ZW418, demonstrating strong activity across RAS-mutated cancers using our novel pan-RAS inhibitor ADC platform Read the full announcement here: loom.ly/bOfLsaM #antibodydrugconjugates

Efficient assembly of unique antibody geometries is a key advantage of our Azymetric platform. Engineering optimal antibody geometries allows interrogation of unique antibody formats that can unlock novel biologies. This requires proprietary amino acid modifications in the heavy and light chains of an IgG-like antibody that enable the transformation of monospecific (single target) antibodies into multispecific antibodies that have alternative target binding formats (e.g. Fabs, scFvs, and VHHs). Learn more about our Azymetric platform: loom.ly/QgN5S3E

In case you missed it! Our Festival of Biologics presentations are now live: Senior Scientist and Group Lead for Multispecific Antibody Therapeutics Anna von Rossum's "Engineering Multispecific Antibodies With Optimal Activity For Oncology and Autoimmune Diseases" is available here: loom.ly/L2_3pmo Senior Scientist Robert Nechanitzky's "ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways" is available here: loom.ly/xBBt_pg

Zymeworks Senior Director, Multispecific Antibody Therapeutics Nina E. Weisser and Director, Medicinal Chemistry Raffaele Colombo will be presenting at ESMO Targeted Anticancer Therapies Congress: March 16-19 (Paris) Raffaele will present on The Path to ADC Discovery on 3/17 at 3:30 PM CET Nina will present on Engineering Trispecific and Multivalent Molecules: Design for Selectivity and Potency on 3/18 at 11:00 AM CET Learn more: loom.ly/2SXVpaA

This #InternationalWomensDay, we’re celebrating the power of shared knowledge. Inspired by this year’s theme “Give to Gain,” women across our company shared advice and lessons that helped shape their careers—and that they now pass on to others. Proud to feature insights from 10 incredible women in our organization. When knowledge is shared, everyone gains.

Today on Employee Appreciation Day, we want to say thank you to everyone at Zymeworks. Every day, our teams bring passion and commitment to advancing our work on behalf of patients around the world. We’re grateful for the people across our company who make this mission possible.

It's a busy conference week in Miami! We hope to see you at Leerink or Citizens - details below. Leerink Annual Global Healthcare Conference: Management will participate in one- on-one meetings and a fireside chat on March 9, 2026 at 15:00 ET in Miami FL. loom.ly/zV5h4bs Citizens Life Science Conference: Management will participate in one-on-one meetings and a fireside chat on March 11, 2026, at 10:10 ET in Miami, FL. loom.ly/e1XG4dI

In case you missed it, check out Stuart Barnscher 's presentation at World ADC London. ZW191: Preclinical Performance Insights to Clinical Potential: loom.ly/otf4BIo #antibodydrugconjugates #drugdevelopment #cancerresearch

Chief Scientific Officer Paul Moore, PhD will be presenting at The ADC Asia Congress 2026 in Singapore March 11-12. This key congress brings together leaders from Singapore, China, Japan, South Korea, Australia, and the broader Asia-Pacific region. We hope to see you there! #antibodydrugconjugates #cancerresearch #drugdevelopment

Zymeworks is pleased to announce a $250 million royalty-backed note financing with Royalty Pharma . Learn more: loom.ly/KUCbyIY

Zymeworks is pleased to announce our Q4 Fourth Quarter and Full Year 2025 Financial Results. To learn more, please see our press release loom.ly/SH_4CVE or join the webcast with management today at 8:30 am ET loom.ly/Nf9PPgs.

March is Autoimmune Awareness Month. It is a time to recognize the 50 million people in the US—and many more globally—impacted by autoimmune diseases. Together we can help their voices be heard, and to advocate for enhanced understanding, support, and research. To learn more about the more than 100 identified autoimmune diseases and their impact, please visit the Autoimmune Association: loom.ly/Z-N4FIU

As we wrap up our 2026 series on Black History Month and turning scientific innovation into meaningful impact, we highlight Dr. Percy Lavon Julian (1899-1975) and innovation in inflammation. Dr. Julian was a US research chemist, entrepreneur, and early trailblazer in the chemical synthesis of medicinal drugs from plants. Julian's pioneering research helped make cortisone, a crucial anti-inflammatory, affordable and widely available. Julian started his own company to synthesize steroid intermediates from yams. This sharply reduced production costs and significantly expanded the use of not only synthetic cortisone—but other key drugs as well. Throughout his career, Julian was granted more than 130 patents. #blackhistorymonth #inflammation #research #drugdevelopment

Zymeworks’ management is looking forward to the TD Cowen 46th Annual Health Care Conference in Boston. The team will join a fireside chat on March 2, 2026 at 2:30 pm ET and participate in one-on-one meetings throughout. Listen to the webcast: loom.ly/1Nj1VnE

Zymeworks Senior Scientist and Group Lead for Multispecific Antibody Therapeutics Anna von Rossum and Senior Scientist Robert Nechanitzky will be presenting at @festofbiologics USA March 4-5 in San Diego. Anna's presentation: Engineering Multispecific Antibodies With Optimal Activity For Oncology and Autoimmune Diseases. Robert's presentation: ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways. See you in San Diego!

As our Black History Month series continues, we’re honoring Dr. LaSalle D. Leffall Jr. (1930-2019) — a surgical oncologist, educator, and national leader who advanced equity in #cancer care. In 1978, he became the first Black president of @AmericanCancer , launching its first national cancer disparities initiative to address the rising burden of cancer in Black communities — a program that became a model for equitable care. He later served as the first Black president of @AmCollSurgeons , led @SocSurgOnc, and chaired the @SusanGKomen Breast Cancer Foundation, championing minority outreach, screening, and access to treatment. Appointed by both George W. Bush and @BarackObama to lead the President’s Cancer Panel, Dr. Leffall advised the White House on cancer policy, disparities, and national prevention strategies — leaving a lasting impact on cancer care in the United States. #blackhistorymonth #cancerresearch

Our series on Black History Month and turning scientific innovation into meaningful impact continues. Today we are highlighting the "Mother of Chemotherapy" and @ASCO co-founder Dr. Jane Cooke Wright (1919-2013). Dr. Cooke- Wright's career was filled with incredible achievements that pushed #cancer research and care forward, some of which include: -Developed the technique of using human tissue culture to test the effects of potential drugs on cancer cells -Pioneered the use of methotrexate to treat breast cancer and skin cancer -Was appointed by President Lyndon B. Johnson, Wright served on the National Cancer Advisory Board -Helmed the Chemotherapy Department, New York Medical College -Elected first female president of the New York Cancer Society #blackhistorymonth #cancerresearch